uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Drug combination screening for mebendazole for the treatment of colorectal cancer
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences.
Show others and affiliations
(English)Manuscript (preprint) (Other academic)
National Category
Medical and Health Sciences
Research subject
Clinical Pharmacology
Identifiers
URN: urn:nbn:se:uu:diva-336682OAI: oai:DiVA.org:uu-336682DiVA, id: diva2:1166655
Available from: 2017-12-15 Created: 2017-12-15 Last updated: 2018-01-09
In thesis
1. Drug Repositioning for Cancer Treatment: Novel Candidate Identification Strategies
Open this publication in new window or tab >>Drug Repositioning for Cancer Treatment: Novel Candidate Identification Strategies
2018 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Regardless of the enormous investments in cancer research and drug development, the proportion of approved drugs in oncology is low compared to other indications, and new avenues are needed. One attractive approach in this regard is drug repositioning where new uses outside the scope of the original medical indications for existing drugs are identified. It offers the advantages of reduced development risks, time and cost over de novo drug discovery pathways.

The main focus of this thesis was to explore and employ different strategies to identify repurposable drug candidates for treatment of cancer. Aiming for this, in the first project we followed a bioinformatics approach to evaluate PDE3A as a drug target and biomarker. We showed that subgroups of tumors, within many different cancer types, overexpress PDE3A (mRNA and protein) and that PDE3A can predict sensitivity to the clinically tested phosphodiesterase inhibitors zardaverine and quazinone (Paper I). In the second project, a novel automated image based microscopy assay was developed and used for detection of apoptotic cells. In a screen the method was successfully used to identify apoptosis inducing compounds. Two of these apoptosis inducers were found to have repurposing potential (Paper II). Moreover, high-throughput combination screening was performed using different cell models. In paper III, monolayer cell cultures were used as cell model to search for combination partners for the anti-parasitic compound mebendazole (a repurposing candidate). As a result, the antipsychotic drug thioridazine was found to have synergistic effect when combined with mebendazol. Finally, a novel drug-combination platform for three-dimensional cell culture based screening, in 384 well formats, was developed. This assay was used to search for combination partners to the anti-parasitic compound nitazoxanide (a repurposing candidate), which was previously reported to specifically target quiescent cancer cells. The screen identified the antifungal agent ketoconazole as selectively toxic to hypoxic and nutrient deprived cancer cells when combined with nitazoxanide (Paper IV). Thus, we have developed/explored several methodological approaches and identified drugs that potentially can be repurposed for treatment of cancer. 

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2018. p. 40
Series
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 1651-6206 ; 1416
Keywords
cancer treatment, drug repositioning, Phosphodiesterase 3A (PDE3A), apoptosis, combination screening
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:uu:diva-338327 (URN)978-91-513-0203-4 (ISBN)
Public defence
2018-02-28, Rosénsalen, Akademiska sjukhuset, ing 95/96 nbv, Uppsala, 09:00 (English)
Opponent
Supervisors
Available from: 2018-02-05 Created: 2018-01-09 Last updated: 2018-04-04

Open Access in DiVA

No full text in DiVA

Search in DiVA

By author/editor
Nazir, Madiha
By organisation
Department of Medical Sciences
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 51 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf